Quarterly Sales and EPS Roundup:
Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported sales (ttm) of 20.29 Billion, whereas, 20 number of analysts estimated the mean sale of 6263.05 million. The analysts estimated sales for the higher end at 6418 million and lower end at 6081.2 million while the year ago reported sale was 6634.38 million.
8 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 6225.7 million while high and low sale targets are estimated at 6445 million and 5996.46 million respectively.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported earning per shares for the quarter ending Nov 15 BMO at 1.25, whereas, 24 number of analysts estimated the mean EPS at 1.37. The analysts estimated EPS for the higher end at 1.44 and lower end at 1.3 while the year ago reported earnings per share was 1.55.
The company has mean EPS estimate of 1.38 reported by 10 number of analyst for the quarter. The analysts estimated mean EPS at 1.38 while the high and low EPS estimate stand at 1.68 and 1.24 respectively. In contrast to the year ago quarter EPS was at 0. EPS long term mean growth rate estimated by 5 analysts is at 3.26%, whereas, the high and low Long term growth rate estimated at 6.82 and -2.5.
Valuation Ratios of Teva Pharmaceutical Industries Limited (NYSE:TEVA) versus the Industry and Sector:
Let’s have a look at some of the important valuation ratios of the Teva Pharmaceutical Industries Limited (NYSE:TEVA). These ratios are important while doing valuation of the company or the shares of the company.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) currently has P/E (Price to Earnings) ratio of 22.41 while the company’s industry has 29.13 P/E and the sector P/E is 29.87. Similarly, the company’s last 5 years high P/E ratio is 36.05 and low P/E is 13.06, whereas, the industry’s and sector’s high P/E for the past year is 41.74 and 43.94 respectively and low P/E ratio for the last 5 years is 18.34 for the industry and 19.95 for the Sector.
Beta is also an important valuation ratio for analyzing the stock of the company, 58 has Beta of 0.68 while its industry and Sector’s beta remains at 0.84 and 0.83 respectively.
Price to Sale ratio of 58 stands at 1.94 while Price to Book Ratio stands at 1.25. Its Price to Cash Flow ratio shows the value of 17.33, whereas, the industry and sector ratio of Price to Cash Flow ticked at 22.73 and 22.64 respectively.
5 Year Growth Rate Analysis:
Growth rates are very important while analyzing the long term growth and valuation of a certain company.
5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands at 4.04 while the industry’s and the sector’s growth for next 5 years ticked at 10.56 and 10.88 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at -13.06 and 1.69.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Trading Statistics:
The company declined -0.42% and closed its last trading session at $37.86. The market capitalization of the company is at $38.05 Billion. The stock touched 52-week High of $66.55 on Dec 30, 2015 and 52-week Low of $37.12 on Nov 23, 2016. The stock currently has Weekly Volatility of 1.91% and Monthly Volatility of 3.56%. The Beta for the company stands at 0.66 and its Average True Range (ATR) shows a value of 1.25.